Earnings per share

12 Months Ended

Jun. 30, 2021

Note 31. Earnings per share


	2021 A$’000			2020 A$’000			2019 A$’000
Loss after income tax attributable to the owners of Kazia Therapeutics Limited		(8,422	)		(12,467	)		(10,270	)

Loss after income tax attributable to the owners of Kazia Therapeutics Limited		(8,422	)		(12,467	)		(10,270	)


	Number			Number			Number
Weighted average number of ordinary shares used in calculating basic earnings per share		117,674,543			73,053,514			57,503,555

Weighted average number of ordinary shares used in calculating Diluted earnings per share		117,674,543			73,053,514			57,503,555


	Cents			Cents			Cents
Basic earnings per share		(7.16	)		(17.07	)		(17.86	)
Diluted earnings per share		(7.16	)		(17.07	)		(17.86	)

1,865,000 unlisted convertible notes with a face value of A$464,000 and 4,446,500 unlisted options have been excluded from the above calculations as they were antidilutive.